ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population

ClinicalTrials.gov ID: NCT04626024

Public ClinicalTrials.gov record NCT04626024. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 5, 2026, 9:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Safety And Efficacy Of Tyrosine Kinase Inhibitor Cessation For Chronic Myeloid Leukemia Patients With Stable Molecular Response In A Real World Population

Study identification

NCT ID
NCT04626024
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Baylor College of Medicine
Other
Enrollment
17 participants

Conditions and interventions

Interventions

  • Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Re-initiation Drug
  • Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Withdrawal Other

Drug · Other

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 21, 2020
Primary completion
Nov 14, 2028
Completion
Nov 14, 2028
Last update posted
May 3, 2026

2020 – 2028

United States locations

U.S. sites
4
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
Baylor College of Medicine- McNair Campus Houston Texas 77030
Ben Taub General Hospital Houston Texas 77030
CHI St. Luke's Health Baylor College of Medicine Medical Center Houston Texas 77030
Harris Health System- Smith Clinic Houston Texas 77054

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04626024, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 3, 2026 · Synced May 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04626024 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →